MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 130 filers reported holding MERSANA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27,368 | -59.3% | 21,550 | +5.4% | 0.00% | – |
Q2 2023 | $67,284 | -10.9% | 20,451 | +11.3% | 0.00% | – |
Q1 2023 | $75,550 | -36.1% | 18,382 | -8.8% | 0.00% | – |
Q4 2022 | $118,143 | -3.2% | 20,161 | +11.3% | 0.00% | – |
Q3 2022 | $122,000 | +52.5% | 18,110 | +4.1% | 0.00% | – |
Q2 2022 | $80,000 | -9.1% | 17,399 | -21.1% | 0.00% | – |
Q1 2022 | $88,000 | -45.3% | 22,048 | -14.4% | 0.00% | – |
Q4 2021 | $161,000 | -30.3% | 25,767 | +5.2% | 0.00% | -100.0% |
Q3 2021 | $231,000 | -43.9% | 24,499 | -19.3% | 0.00% | 0.0% |
Q2 2021 | $412,000 | +7.0% | 30,366 | +27.7% | 0.00% | 0.0% |
Q1 2021 | $385,000 | -35.3% | 23,779 | +6.3% | 0.00% | -50.0% |
Q4 2020 | $595,000 | +440.9% | 22,364 | +103.6% | 0.00% | +100.0% |
Q3 2018 | $110,000 | -45.3% | 10,982 | -2.5% | 0.00% | 0.0% |
Q2 2018 | $201,000 | +6.9% | 11,264 | -5.7% | 0.00% | 0.0% |
Q1 2018 | $188,000 | -12.1% | 11,950 | -8.1% | 0.00% | 0.0% |
Q4 2017 | $214,000 | – | 13,008 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |